In this retrospective pooled analysis of 3 randomized clinical trials including 1289 patients with ERBB2/HER2-positive EBC, the association between pCR and EFS differed by tumor intrinsic subtype, and the benefit of dual ERBB2/HER2-blockade was limited to ERBB2-enriched tumors. This evidence concerns the gene ERBB2 and neoplasm.